Terms: = Leukemia AND NTRK3, TRKC, 4916, ENSG00000140538, Q16288, gp145 trkC AND Treatment
12 results:
1. Targeted therapy using larotrectinib and venetoclax for the relapsed/refractory T-cell acute lymphoblastic leukemia harboring a cryptic ETV6-ntrk3 fusion.
Zhou K; Gong D; He C; Xiao M; Zhang M; Huang W
Mol Carcinog; 2023 Jul; 62(7):899-906. PubMed ID: 37036164
[TBL] [Abstract] [Full Text] [Related]
2. Larotrectinib in TRK fusion-positive pediatric B-cell acute lymphoblastic leukemia.
Schewe DM; Lenk L; Vogiatzi F; Winterberg D; Rademacher AV; Buchmann S; Henry D; Bergmann AK; Cario G; Cox MC
Blood Adv; 2019 Nov; 3(22):3499-3502. PubMed ID: 31725893
[TBL] [Abstract] [Full Text] [Related]
3. A Case of Papillary Thyroid Carcinoma and Kostmann Syndrome: A Genomic Theranostic Approach for Comprehensive treatment.
Han S; Ehrhardt J; Shukla S; Elkbuli A; Nikiforov YE; Gulec SA
Am J Case Rep; 2019 Jul; 20():1027-1034. PubMed ID: 31308356
[TBL] [Abstract] [Full Text] [Related]
4. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group.
Roberts KG; Reshmi SC; Harvey RC; Chen IM; Patel K; Stonerock E; Jenkins H; Dai Y; Valentine M; Gu Z; Zhao Y; Zhang J; Payne-Turner D; Devidas M; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Mattano LA; Maloney KW; Carroll WL; Loh ML; Willman CL; Gastier-Foster JM; Mullighan CG; Hunger SP
Blood; 2018 Aug; 132(8):815-824. PubMed ID: 29997224
[TBL] [Abstract] [Full Text] [Related]
5. Insulin-like growth factor 1 receptor stabilizes the ETV6-ntrk3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation.
Tognon CE; Rafn B; Cetinbas NM; Kamura T; Trigo G; Rotblat B; Okumura F; Matsumoto M; Chow C; Davare M; Pollak M; Mayor T; Sorensen PH
J Biol Chem; 2018 Aug; 293(32):12502-12515. PubMed ID: 29903916
[TBL] [Abstract] [Full Text] [Related]
6. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in
Smith KM; Fagan PC; Pomari E; Germano G; Frasson C; Walsh C; Silverman I; Bonvini P; Li G
Mol Cancer Ther; 2018 Feb; 17(2):455-463. PubMed ID: 29237803
[TBL] [Abstract] [Full Text] [Related]
7. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
Reshmi SC; Harvey RC; Roberts KG; Stonerock E; Smith A; Jenkins H; Chen IM; Valentine M; Liu Y; Li Y; Shao Y; Easton J; Payne-Turner D; Gu Z; Tran TH; Nguyen JV; Devidas M; Dai Y; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Angiolillo AL; Burke MJ; Salzer WL; Zweidler-McKay PA; Rabin KR; Carroll WL; Zhang J; Loh ML; Mullighan CG; Willman CL; Gastier-Foster JM; Hunger SP
Blood; 2017 Jun; 129(25):3352-3361. PubMed ID: 28408464
[TBL] [Abstract] [Full Text] [Related]
8. ETV6-ntrk3 as a therapeutic target of small molecule inhibitor PKC412.
Chi HT; Ly BT; Kano Y; Tojo A; Watanabe T; Sato Y
Biochem Biophys Res Commun; 2012 Dec; 429(1-2):87-92. PubMed ID: 23131561
[TBL] [Abstract] [Full Text] [Related]
9. leukemias induced by altered TRK-signaling are sensitive to mTOR inhibitors in preclinical models.
Rhein M; Schwarzer A; Yang M; Kaever V; Brugman M; Meyer J; Ganser A; Baum C; Li Z
Ann Hematol; 2011 Mar; 90(3):283-92. PubMed ID: 20821325
[TBL] [Abstract] [Full Text] [Related]
10. Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells.
Rink L; Slupianek A; Stoklosa T; Nieborowska-Skorska M; Urbanska K; Seferynska I; Reiss K; Skorski T
Blood; 2007 Jul; 110(2):651-60. PubMed ID: 17431132
[TBL] [Abstract] [Full Text] [Related]
11. Role of nerve growth factor and its receptors in non-nervous cancer growth: efficacy of a tyrosine kinase inhibitor (AG879) and neutralizing antibodies antityrosine kinase receptor A and antinerve growth factor: an in-vitro and in-vivo study.
Rende M; Pistilli A; Stabile AM; Terenzi A; Cattaneo A; Ugolini G; Sanna P
Anticancer Drugs; 2006 Sep; 17(8):929-41. PubMed ID: 16940803
[TBL] [Abstract] [Full Text] [Related]
12. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.
Slupianek A; Hoser G; Majsterek I; Bronisz A; Malecki M; Blasiak J; Fishel R; Skorski T
Mol Cell Biol; 2002 Jun; 22(12):4189-201. PubMed ID: 12024032
[TBL] [Abstract] [Full Text] [Related]
